117 related articles for article (PubMed ID: 38843120)
21. Novel tablet formulation of amorphous candesartan cilexetil solid dispersions involving P-gp inhibition for optimal drug delivery: in vitro and in vivo evaluation.
Surampalli G; Nanjwade BK; Patil PA; Chilla R
Drug Deliv; 2016 Sep; 23(7):2124-2138. PubMed ID: 25080228
[TBL] [Abstract][Full Text] [Related]
22. Comparative Pharmaceutical Evaluation of Candesartan and Candesartan Cilexetil: Physicochemical Properties, In Vitro Dissolution and Ex Vivo In Vivo Studies.
Amer AM; Allam AN; Abdallah OY
AAPS PharmSciTech; 2018 Feb; 19(2):661-667. PubMed ID: 28948575
[TBL] [Abstract][Full Text] [Related]
23. HPMCAS as an effective precipitation inhibitor in amorphous solid dispersions of the poorly soluble drug candesartan cilexetil.
Pinto JMO; Leão AF; Riekes MK; França MT; Stulzer HK
Carbohydr Polym; 2018 Mar; 184():199-206. PubMed ID: 29352911
[TBL] [Abstract][Full Text] [Related]
24. Effects of Polymers on the Drug Solubility and Dissolution Enhancement of Poorly Water-Soluble Rivaroxaban.
Choi MJ; Woo MR; Choi HG; Jin SG
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012748
[TBL] [Abstract][Full Text] [Related]
25. Solid lipid nanoparticles loading candesartan cilexetil enhance oral bioavailability: in vitro characteristics and absorption mechanism in rats.
Zhang Z; Gao F; Bu H; Xiao J; Li Y
Nanomedicine; 2012 Jul; 8(5):740-7. PubMed ID: 21930110
[TBL] [Abstract][Full Text] [Related]
26. Crystalline Ethylene Oxide and Propylene Oxide Triblock Copolymer Solid Dispersion Enhance Solubility, Stability and Promoting Time- Controllable Release of Curcumin.
Alves TFR; das Neves Lopes FCC; Rebelo MA; Souza JF; da Silva Pontes K; Santos C; Severino P; Junior JMO; Komatsu D; Chaud MV
Recent Pat Drug Deliv Formul; 2018; 12(1):65-74. PubMed ID: 29345599
[TBL] [Abstract][Full Text] [Related]
27. Anomalous dissolution behavior of celecoxib in PVP/Isomalt solid dispersions prepared using spray drier.
Ghanavati R; Taheri A; Homayouni A
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():501-511. PubMed ID: 28024614
[TBL] [Abstract][Full Text] [Related]
28. Developing pH-Modulated Spray Dried Amorphous Solid Dispersion of Candesartan Cilexetil with Enhanced In Vitro and In Vivo Performance.
Poudel S; Kim DW
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917403
[TBL] [Abstract][Full Text] [Related]
29. Microenvironmental pH-modified solid dispersions to enhance the dissolution and bioavailability of poorly water-soluble weakly basic GT0918, a developing anti-prostate cancer drug: preparation, characterization and evaluation in vivo.
Yang M; He S; Fan Y; Wang Y; Ge Z; Shan L; Gong W; Huang X; Tong Y; Gao C
Int J Pharm; 2014 Nov; 475(1-2):97-109. PubMed ID: 25171976
[TBL] [Abstract][Full Text] [Related]
30. Enhancement of solubility and dissolution of cilostazol by solid dispersion technique.
Park JH; Choi HK
Arch Pharm Res; 2015 Jul; 38(7):1336-44. PubMed ID: 25567762
[TBL] [Abstract][Full Text] [Related]
31. Formulation and characterization of glipizide solid dosage form with enhanced solubility.
Alotaibi BS; Khan MA; Ullah K; Yasin H; Mannan A; Khan SA; Murtaza G
PLoS One; 2024; 19(2):e0297467. PubMed ID: 38394326
[TBL] [Abstract][Full Text] [Related]
32. Pharmaceutical Cocrystal: A Novel Approach to Tailor the Biopharmaceutical Properties of a Poorly Water Soluble Drug.
Srivastava D; Fatima Z; Kaur CD; Tulsankar SL; Nashik SS; Rizvi DA
Recent Pat Drug Deliv Formul; 2019; 13(1):62-69. PubMed ID: 30848223
[TBL] [Abstract][Full Text] [Related]
33. Melt dispersion granules: formulation and evaluation to improve oral delivery of poorly soluble drugs - a case study with valsartan.
Chella N; Tadikonda R
Drug Dev Ind Pharm; 2015 Jun; 41(6):888-97. PubMed ID: 24796274
[TBL] [Abstract][Full Text] [Related]
34. The use of polymer blends to improve stability and performance of electrospun solid dispersions: The role of miscibility and phase separation.
Tipduangta P; Belton P; McAuley WJ; Qi S
Int J Pharm; 2021 Jun; 602():120637. PubMed ID: 33901595
[TBL] [Abstract][Full Text] [Related]
35. Formulation and Pharmacokinetic Evaluation of Polymeric Dispersions Containing Valsartan.
Chella N; Daravath B; Kumar D; Tadikonda RR
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):517-26. PubMed ID: 26156887
[TBL] [Abstract][Full Text] [Related]
36. Egg White Protein Carrier-Assisted Development of Solid Dispersion for Improved Aqueous Solubility and Permeability of Poorly Water Soluble Hydrochlorothiazide.
Telange DR; Jain SP; Pethe AM; Kharkar PS
AAPS PharmSciTech; 2021 Mar; 22(3):94. PubMed ID: 33683493
[TBL] [Abstract][Full Text] [Related]
37. Development and characterization of mixed niosomes for oral delivery using candesartan cilexetil as a model poorly water-soluble drug.
Sezgin-Bayindir Z; Antep MN; Yuksel N
AAPS PharmSciTech; 2015 Feb; 16(1):108-17. PubMed ID: 25204859
[TBL] [Abstract][Full Text] [Related]
38. Understanding the interaction between Soluplus® and biorelevant media components.
Pinto JMO; Rengifo AFC; Mendes C; Leão AF; Parize AL; Stulzer HK
Colloids Surf B Biointerfaces; 2020 Mar; 187():110673. PubMed ID: 31812452
[TBL] [Abstract][Full Text] [Related]
39. Electrosprayed Polymeric Nanospheres for Enhanced Solubility, Dissolution Rate, Oral Bioavailability and Antihyperlipidemic Activity of Bezafibrate.
Sun R; Shen C; Shafique S; Mustapha O; Hussain T; Khan IU; Mehmood Y; Anwer K; Shahzad Y; Yousaf AM
Int J Nanomedicine; 2020; 15():705-715. PubMed ID: 32099359
[TBL] [Abstract][Full Text] [Related]
40. Development and in vitro/in vivo performance of self-nanoemulsifying drug delivery systems loaded with candesartan cilexetil.
AboulFotouh K; Allam AA; El-Badry M; El-Sayed AM
Eur J Pharm Sci; 2017 Nov; 109():503-513. PubMed ID: 28889028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
